Quantitative gene-expression of the tumor angiogenesis markers vascular endothelial growth factor, integrin αV and integrin β3 in human neuroendocrine tumors

  • Authors:
    • Jytte Oxboel
    • Tina Binderup
    • Ulrich Knigge
    • Andreas Kjaer
  • View Affiliations

  • Published online on: March 1, 2009     https://doi.org/10.3892/or_00000283
  • Pages: 769-775
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Anti-angiogenesis treatment is a promising new therapy for cancer that recently has also been suggested for patients with neuroendocrine tumors. The aim of the present study was therefore to investigate the level of tumor angiogenesis, and thereby the molecular basis for anti-angiogenesis treatment, in neuroendocrine tumors. We used quantitative real-time PCR for measuring mRNA gene-expression of vascular endothelial growth factor (VEGF), integrin αV, and integrin β3, and CD34 for a group of patients with neuroendocrine tumors (n=13). Tissue from patients with colorectal cancer liver metastases (n=14) and normal liver tissues (n=16) was used as control. We found a lower mRNA level of VEGF in neuroendocrine tumors compared to both colorectal liver metastases (p<0.001) and normal liver tissue (p<0.01). For integrin β3 there was also a borderline significant lower level of mRNA in neuroendocrine tumors compared to both colorectal liver metastases (p=0.10) and normal liver tissue (p=0.06). In neuroendocrine tumors, gene-expression was highly variable of VEGF (530-fold), integrin αV (23-fold) and integrin β3 (106-fold). Quantitative gene-expression levels of the key angiogenesis molecules VEGF and integrin β3 were lower in neuroendocrine tumors than in colorectal liver metastases and were highly variable. Therefore, individual selection of patients may be necessary if anti-angiogenesis treatment is to be successful in patients with neuroendocrine tumors.

Related Articles

Journal Cover

March 2009
Volume 21 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Oxboel J, Binderup T, Knigge U and Kjaer A: Quantitative gene-expression of the tumor angiogenesis markers vascular endothelial growth factor, integrin αV and integrin β3 in human neuroendocrine tumors. Oncol Rep 21: 769-775, 2009.
APA
Oxboel, J., Binderup, T., Knigge, U., & Kjaer, A. (2009). Quantitative gene-expression of the tumor angiogenesis markers vascular endothelial growth factor, integrin αV and integrin β3 in human neuroendocrine tumors. Oncology Reports, 21, 769-775. https://doi.org/10.3892/or_00000283
MLA
Oxboel, J., Binderup, T., Knigge, U., Kjaer, A."Quantitative gene-expression of the tumor angiogenesis markers vascular endothelial growth factor, integrin αV and integrin β3 in human neuroendocrine tumors". Oncology Reports 21.3 (2009): 769-775.
Chicago
Oxboel, J., Binderup, T., Knigge, U., Kjaer, A."Quantitative gene-expression of the tumor angiogenesis markers vascular endothelial growth factor, integrin αV and integrin β3 in human neuroendocrine tumors". Oncology Reports 21, no. 3 (2009): 769-775. https://doi.org/10.3892/or_00000283